text stringlengths 1 5.46k |
|---|
For all three programs, Capsida will lead capsid discovery efforts using its high throughput AAV engineering and screening platform and AbbVie will contribute innovative therapeutic approaches. Capsida will also be responsible for process development and early clinical manufacturing of all programs. |
"We are excited to enter this licensing agreement with Capsida. By combining Capsida's deep understanding of the structure-function relationship of AAV biology with AbbVie's innovative cargo therapeutic technologies, we will strive to develop highly effective and transformative gene therapies for patients with devastat... |
Capsida operating plans |
Capsida's initial internal preclinical programs center on neurodevelopmental and neurodegenerative disorders, areas in which gene therapies have yet to gain significant traction due to the difficulties of targeting the brain. Based on progress to date, Capsida expects to start IND-enabling work on its first development... |
In addition to continuing preclinical work on its lead assets, the company plans to use proceeds from its $50 million Series A financing to open its state-of-the-art manufacturing facility this year and advance its platform into non-CNS disorders. |
The company is operating from its site in Thousand Oaks, California. |
"Capsida is another example of the growing biotech hub in the Greater Los Angeles area," said Beth Seidenberg, M.D., founding managing director at Westlake Village BioPartners and a Capsida board member. "Westlake Village BioPartners is proud to be catalyzing this growth. Capsida is led by an outstanding team of execut... |
With the anchor investment from Versant and Westlake, and the collaboration with AbbVie, Capsida plans to expand its 50-member team to about 100 scientists this year. To capture the expanding opportunities in the field of gene therapy, Capsida will pursue additional strategic opportunities in parallel with financial in... |
About Capsida Biotherapeutics |
Capsida Biotherapeutics Inc. is developing tissue-targeted gene therapies using its biologically driven, high-throughput adeno-associated virus (AAV) engineering and proprietary cargo development platform. As a fully integrated gene therapy company, Capsida is combining its differentiated AAV engineering and screening ... |
About Versant Ventures |
Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm's emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With $4.2 billion under management and offices in the U.S.,... |
About Westlake Village BioPartners |
Westlake Village BioPartners is a Los Angeles area-based venture capital firm focused on incubating and building life sciences companies with entrepreneurs who have the potential to bring transformative therapies to patients. Westlake manages more early stage venture capital solely from the greater Los Angeles area tha... |
Media Contacts: |
Versant Steve Edelson (415) 801-8088 sedelson@versantventures.com |
Westlake Village BioPartners Greig Communications, Inc. Kathy Vincent (310) 403-8951 kathy@greigcommunications.com |
# # # |
SCHEDULE 11.5B |
AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need |
- Partnership Combines AbbVie's extensive capabilities with Capsida's novel adeno-associated virus (AAV) engineering platform - Builds upon the neurodegenerative disease partnership announced in 2021 |
NORTH CHICAGO, Ill. and THOUSAND OAKS, Calif. – February 23, 2023 – AbbVie (NYSE: ABBV) and Capsida Biotherapeutics Inc. ("Capsida") today announced an expanded strategic collaboration to develop genetic medicines for eye diseases with high unmet need. AbbVie's extensive capabilities will be paired with Capsida's novel... |
"This expanded collaboration with Capsida has the potential to develop transformative therapies for patients with serious eye diseases," said Jonathon Sedgwick, Ph.D., vice president and global head of discovery research, AbbVie. "In pursuing the promise of genetic medicine-based therapeutics, AbbVie continues to expan... |
"AbbVie has been an excellent partner, and we are excited to expand our collaboration into ophthalmology with the world leader in this therapeutic area," said Peter Anastasiou, chief executive officer of Capsida. "Combining AbbVie's expertise in eye disease drug development and commercialization with Capsida's fully in... |
Under the terms of the expanded agreement, Capsida will receive $70 million, consisting of upfront payments and a potential equity investment. For the three programs, Capsida may be eligible to receive up to $595 million in option fees and research and development milestones, with potential for further commercial miles... |
About AbbVie AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and ga... |
About Capsida Biotherapeutics Capsida Biotherapeutics is a fully integrated next-generation gene therapy platform company. Capsida's approach unlocks the potential to treat both rare and common diseases across all ages. We create customized therapies that selectively target specific organ systems and simultaneously lim... |
Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking sta... |
Contacts: |
For AbbVie |
Media Frank Benenati (847) 938-8745 frank.benenati@abbvie.com |
Investors Liz Shea (847) 935-2211 liz.shea@abbvie.com |
For Capsida Kathy Vincent Greig Communications, Inc. kathy@greigcommunications.com |
1 |
SCHEDULE 12.2 |
Initial Neurology Disclosure Schedule |
1 |
SCHEDULE 12.3 |
Initial Ophthalmology Disclosure Schedule |
Intentionally left blank. |
1 |
SCHEDULE 12.2.1 |
A: Existing In-License Agreements as of the Original Agreement Effective Date |
1. License Agreement by and Between Capsida and Caltech dated August 5, 2019 and as amended September 1, 2020 |
2. Life Technologies Cell Line License Agreement by and between Capsida and Life Technologies Corp. dated February 10, 2021. |
3. License Agreement by and between Capsida and Advec Inc dated July 8, 2020. |
B: Future Capsida In-License Agreements for Neurology Program |
1 |
SCHEDULE 12.2.4 |
Existing NP Patents |
[Table containing patent information with columns: BR Ref, Serial Number, Filing Date, Title, Owner, License Type, Status] |
[The table contains multiple patents related to adeno-associated viruses with various filing dates, mostly owned by Caltech with exclusive licenses to Capsida] |
1 |
SCHEDULE 12.3.1 |
A: Existing In-License Agreements as of the Original Agreement Effective Date |
License Agreement by and Between Capsida and Caltech dated August 5, 2019 and as amended September 1, 2020 |
Life Technologies Cell Line License Agreement by and between Capsida and Life Technologies Corp. dated February 10, 2021. |
License Agreement by and between Capsida and Advec Inc dated July 8, 2020. |
B: Future Capsida In-License Agreements for Ophthalmology Program |
SCHEDULE 12.3.4 |
Existing OP Patents |
[Same as 12.2.4 as of the Effective Date] |
1 |
SCHEDULE 15.6.3 |
ADR Procedures |
Any Dispute referred to ADR under this Agreement shall be resolved as follows: |
1. To begin an ADR proceeding, a Party shall provide written notice to the other Party of the Dispute to be resolved by ADR. Within fourteen (14) days after its receipt of such notice, the other Party may, by written notice to the Party initiating the arbitration, add additional issues to be resolved within the same AD... |
2. Within twenty-one (21) days following the initiation of the ADR proceeding, the Parties shall select a mutually acceptable independent, impartial and conflicts-free neutral to preside in the resolution of all issues in this ADR proceeding. If the Parties are unable to agree on a mutually acceptable neutral within su... |
3. No earlier than twenty-eight (28) days or later than fifty-six (56) days after selection, the Neutral shall hold a hearing to resolve each of the issues identified by the Parties. The ADR proceeding shall take place at a location agreed upon by the Parties. If the Parties cannot agree, the Neutral shall designate a ... |
4. At least seven (7) days prior to the hearing, each Party shall submit the following to the other Party and the Neutral: (a) a copy of all exhibits on which such Party intends to rely in any oral or written presentation to the Neutral; (b) a list of any witnesses such Party intends to call at the hearing, and a short... |
5. The hearing shall be conducted on two (2) consecutive days and shall be governed by the following rules: (a) Each Party shall be entitled to five (5) hours of hearing time to present its case. The Neutral shall determine whether each Party has had the five (5) hours to which it is entitled. (b) Each Party shall be e... |
6. Within seven (7) days following completion of the hearing, each Party may submit to the other Party and the Neutral a post-hearing brief in support of its proposed rulings and remedies; provided, that such brief shall not contain or discuss any new evidence and shall not exceed ten (10) pages. This page limitation s... |
7. The Neutral shall rule on each disputed issue within fourteen (14) days following completion of the hearing. Such ruling shall adopt in its entirety the proposed ruling and remedy of one (1) of the Parties on each disputed issue but may adopt one (1) Party's proposed rulings and remedies on some issues and the other... |
8. The Neutral shall be paid a reasonable fee plus expenses. These fees and expenses, along with the reasonable legal fees and expenses of the prevailing Party (including all expert witness fees and expenses), the fees and expenses of a court reporter, and any expenses for a hearing room, shall be paid as follows: (a) ... |
9. The rulings of the Neutral and the allocation of fees and expenses shall be binding, non-reviewable, and non-appealable, and may be entered as a final judgment in any court having jurisdiction. |
10. Except as provided in paragraph 9 or as required by law, the existence of the Dispute, any settlement negotiations, the ADR proceeding, any submissions (including exhibits, testimony, proposed rulings, and briefs), and the rulings shall be deemed to be Confidential Information of both Parties. The Neutral shall hav... |
11. All ADR proceedings shall be conducted in the English language. |
12. Each Party shall have the right to be represented by counsel in all aspects of any ADR proceeding. |
Confidential EXECUTION VERSION |
DB1/ 92622394.30 |
CO-DEVELOPMENT AND OPTION AGREEMENT |
between |
ALECTOR, INC. |
and |
ABBVIE BIOTECHNOLOGY, LTD. |
Dated as of October 16, 2017 |
TABLE OF CONTENTS |
ARTICLE 1 DEFINITIONS .............................................................................................................. 1 |
ARTICLE 2 COLLABORATION MANAGEMENT ..................................................................... 32 |
2.1 Joint Steering Committee ............................................................................................ 32 |
2.2 Joint Development Committee ................................................................................... 33 |
2.3 Joint Commercialization Committee .......................................................................... 34 |
2.4 General Provisions Applicable to Joint Committees .................................................. 35 |
2.5 Discontinuation of Participation on a Committee ....................................................... 38 |
2.6 Interactions Between a Committee and Internal Teams ............................................. 38 |
2.7 Working Groups.......................................................................................................... 38 |
2.8 Information ................................................................................................................. 39 |
2.9 Expenses ..................................................................................................................... 39 |
ARTICLE 3 DEVELOPMENT AND REGULATORY ................................................................. 39 |
3.1 Pre Exercise Development Plan and Activities .......................................................... 39 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.